IMNM earnings analysis
What we found in IMNM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Immunome remains a development-stage biotechnology company with $0 revenue, a $73.1 million quarterly net loss and diluted EPS of negative $0.65, with losses worsening versus the prior-year EPS of negative $0.50. Liquidity is a meaningful offset: cash, cash equivalents and marketable securities totaled approximately $520.0 million at June 30, 2026, with no debt and management expecting funding for at least 12 months from filing. Varegacestat’s NDA acceptance and April 28, 2027 PDUFA date are positive pipeline developments, but regulatory approval, continued capital needs and the absence of commercial revenue keep the risk/reward profile unfavorable.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No current product revenue
- Revenue was $0 for the quarter, versus $4 million in the prior-year quarter, confirming that the company has not yet generated product-sale revenue.
- Varegacestat reaches FDA review
- Varegacestat’s NDA was accepted by the FDA and assigned a PDUFA target action date of April 28, 2027, advancing the lead program into formal regulatory review.
- Strong liquidity position
- The company held $217.7 million of cash and cash equivalents plus $302.3 million of marketable securities, totaling approximately $520.0 million of liquidity at June 30, 2026.
- Debt-free balance sheet
- The company had no outstanding debt as of June 30, 2026, limiting near-term balance-sheet refinancing risk.
- Liquidity runway exceeds 12 months
- Management stated that existing liquidity should fund current and planned operating expenses and capital expenditures for at least 12 months from the August 11, 2026 filing date.
- Controls remained effective
- Disclosure controls and procedures were assessed as effective at the reasonable-assurance level as of June 30, 2026, with no material changes in internal control during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and EPS deterioration
- The quarterly net loss was $73.1 million and diluted EPS was negative $0.65, compared with diluted EPS of negative $0.50 in the prior-year quarter. The company reported a $127.0 million net loss for the six months ended June 30, 2026 and expects significant losses to continue.
- Ongoing capital-raising and dilution risk
- The company had an accumulated deficit of $855.1 million as of June 30, 2026 and stated that it may need substantial additional funding to advance its product candidates and ADC platform. Additional financing could dilute existing holders; the 2024 ATM had approximately $134.1 million remaining available for future sales.
- Regulatory approval remains uncertain
- Varegacestat’s NDA has a PDUFA target action date of April 28, 2027, but the company has not previously obtained FDA marketing approval or commercialized a product. The filing states that the NDA may not be approved and that approval could be delayed or limited.
- Radioligand supply and competition
- IM-3050’s Phase 1 trial commencement was delayed by shipment of its diagnostic radiotracer, and the company relies on limited suppliers for that material. The filing also identifies competition from FAP-targeted radioligand programs at 4 named companies: Novartis, Ratio Therapeutics, Perspective Therapeutics and Sinotau Pharmaceutical Group.
- Expanding privacy and AI compliance risk
- The filing adds or updates material exposure to evolving data-privacy and AI regulation, including potential EU AI Act fines of up to €35 million or 7% of worldwide annual turnover and EU GDPR fines of up to €20 million or 4% of annual global revenue.
- Capacity and hiring requirements
- The company had 247 full-time employees as of June 30, 2026 and stated that material additional staffing will be required within the next 12 months, creating execution and retention risk as the pipeline advances.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.65
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management said cash, cash equivalents and marketable securities of $520.0 million as of June 30, 2026 would fund current and planned operating expenses and capital expenditures for at least 12 months from the filing date; the prior 8-K indicated liquidity was expected to fund operations into 2028.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- Immunome, Inc. (IMNM) reported a challenging Q1 2026 with a revenue of $0, missing estimates and a net loss of $53.8 million. The company continues to increase R&D spending following NDA submission for varegacestat,…
- 10-K · March 3, 2026
- Immunome (IMNM) is a clinical-stage oncology company built around ADC discovery and a recently acquired GSI, varegacestat. The company reported highly positive Phase 3 RINGSIDE topline results in December 2025 (HR=0.16,…
- 10-Q · November 6, 2025
- Immunome reported Q3 2025 net loss of $(57,457) (per share loss $0.65) on collaboration revenue of $0 versus $2,910 in Q3 2024; operating loss widened to $(60,138) from $(50,522). Cash and cash equivalents increased to…
- 10-Q · August 12, 2024
- Immunome reported collaboration revenue of $2,364,000 for the quarter ended June 30, 2024 (down from $4,263,000 a year ago) and a GAAP net loss of $36,122,000 (loss per share $0.60). Operating expense jumped to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IMNM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever